Dr Harper has over 30 years' experience of the  life sciences industry covering both drug development and medical devices.  He has served as Chief Executive of Cambridge Antibody Technology Ltd and Provensis Ltd.  He has also served as Corporate Development  Director of Unipath, then the medical diagnostics business of Unilver, and as Director of Reneuron Holdings plc and Physiomics plc, all AIM quoted companies.  In addition, he is Chairman of RegenTec Ltd, FDAS Ltd, Physiomics plc and Monica Healthcare Ltd.  Formerly head of Antimicrobial Chemotherapy for Glaxo, Dr Harper holds a  doctorate in molecular virology and is the author of over 50  publications. 

Dr Harper is Chair of Angel's Remuneration Committee; the role of the Committee is to establish a formal and transparent policy on executive remuneration and to set remuneration packages for individual Directors.

Gordon Sherriff trained as an Immunologist and has over 26 years' experience in biologics manufacturing gained with the National Blood Service, International Blood Reference Laboratory in Oxford, Bio-Products Laboratory in London, Serologicals Inc. and Excell Biotech Ltd, of which he was a co-founder. He has held a number of senior scientific, operational, technical and managerial roles. He has significant cGMP manufacturing, process development and quality systems experience having been responsible for the implementation in three organisations of MHRA (formerly MCA) manufacturer's licences and ISO 9001 certification. He has also successfully maintained an FDA manufacturer's licence and has significant regulatory experience including CMC element and IND submissions. As a result, Mr Sherriff has a detailed understanding of regulatory issues and customer needs and concerns when contracting out their development and cGMP manufacturing.

Gavin Clark has 25 years experience in the life sciences sector holding senior positions in the industry before forming his own practice Procela Partners Limited.  He was responsible for Global Licensing for infectious diseases at Glaxo Wellcome until 1999 and served as VP Business Development for Tibotec Pharmaceuticals up until the acquisition by Johnson & Johnson in 2002.   His extensive licensing & commercial development experience encompasses Global, Regional, Drug Delivery, Diagnostics and Generics deals from both big and small sides of the negotiating table.  Mr Clark has a bachelors degree in Chemistry from the University of Strathclyde.

Mr Clark is a member of the Audit Committee and the Remuneration Commitee